In the current issue of the journal, conclude, on the basis of quality A evidence, with recommendations against using iNO to reduce mortality and morbidity in preterm infants with respiratory failure. The findings of Ellsworth et al are probably generalizable. They cite a usage rate of 6.9% for a comparable preterm cohort in the Vermont Oxford Network and review of data in the same gestational group from the New South Wales/ Australian Capital Territory network (by NE) shows a rate of 7.2%.
So why this continued use of iNO, considering the strength of evidence against using this expensive treatment? There would seem to be 3 possibilities: first and least likely, lack of awareness of the evidence; second and more likely, a view that the evidence is not generalizable to a particular situation; or third and most likely, that, despite the evidence, the neonatal intensivists' instinct to attempt to normalize physiology prevails when faced with a hypoxic ventilated baby.
We speculate that iNO is being mainly used in 2 clinical scenarios: first, during acute crises of oxygenation in the first week or two of life and, second, in infants with evolving chronic lung disease with suspected or documented pulmonary hypertension. The evidence against using iNO is strongest in the first of these scenarios. Meta-analysis is not perfect and cannot, even through sophisticated statistical manipulation, account for differences in aspects of patient care, unit practices, and individual patient differences. It was for this reason that the individual patient data metaanalysis was facilitated with the cooperation of the iNO trial principal investigators. This also showed no benefits from iNO stratifying for a range of variables, including oxygenation index, making it difficult to argue that the evidence is not generalizable to the sickest infants.
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Our speculation would be that usage is being driven mainly by the intensivists' desire to normalize physiology in critical clinical situations. This would be fine if there were no harms or costs, but there are. Trends to increased adverse outcome are seen in the smallest infants (,1000 g), and the financial costs of this treatment are significant, estimated by Ellsworth et al at $153 million for infants born at ,34 weeks in the United States.
iNO has many effects on the lungs, but is mainly used as a pulmonary vasodilator. The premise to evaluate iNO in preterm infants was based on the view that preterm infants in respiratory failure often had unrecognized pulmonary hypertension (PH). It is a shortcoming of the evidence that none of the large trials required ultrasound diagnosis of PH, and thus one cannot determine whether infants with proven PH had a benefit from iNO compared with those who did not. We would propose that thresholds should be set on the basis of ultrasound criteria that would define PAP at or above a normal systemic pressure, so as to encompass only infants with unequivocally pathologic PH.
The proposed guidelines need to leave room for individual clinician judgment but could require parental consent by using a consent document approved by the institutional review board with agreed language before iNO is used. The risk for iNO appears to be highest and efficacy lowest for infants weighing ,1000 g at birth, and this could be the first target population of such an approach. There could be a mandated checklist before iNO initiation in such infants that requires optimizing all aspects of care and ensuring adequate diagnostic studies. These approaches would highlight the uncertainty of using iNO in the very preterm infants to physicians and other health care workers, as well as parents. In addition, these measures could be initiated with an audit tool for allowing a monthly review of iNO use and the infants' outcomes. It would also serve to identify such infants for longer-term follow-up, if they are not already in a known risk group.
More generally, there is a need for specifically focused trials of iNO on preterm infants with evidence of PH, and perhaps other specific conditions, such as prolonged oligohydramnios, to determine if there are conditions in this population for which iNO may improve outcomes. Such trials should have enrollment criteria that will define pathologic PH, as discussed previously. These studies will require significant collaboration and the current information about usage and the associated costs should encourage and stimulate such trials. In addition, a review of a large number of very preterm infants with PH that would include their longerterm neurodevelopmental outcomes would be very helpful, and perhaps a registry of such patients could be developed for this purpose. The existing European Inhaled Nitric Oxide Registry (www.medscinet.net/ ino/, iNORegistry@lwh.nhs.uk) may be a useful resource in this endeavor.
There would need to be agreed-on diagnostic criteria, and details of the infants' management, which would facilitate an understanding of the morbidity and mortality of such infants.
In conclusion, the evidence does not justify the current rates of usage of iNO in preterm infants. This treatment is hugely expensive and may be harmful in the smallest infants. There is a need for a local and collective effort to rationalize this usage through development of clinical guidelines and more targeted clinical trials. 
